Target Name: FGFR4
NCBI ID: G2264
Review Report on FGFR4 Target / Biomarker Content of Review Report on FGFR4 Target / Biomarker
FGFR4
Other Name(s): Fibroblast growth factor receptor 4, transcript variant 5 | Fibroblast growth factor receptor 4 | fibroblast growth factor receptor 4 | FGFR-4 | Fibroblast growth factor receptor 4, transcript variant 3 | tyrosine kinase related to fibroblast growth factor receptor | TKF | Fibroblast growth factor receptor 4, transcript variant 2 | FGFR4 variant 1 | Fibroblast growth factor receptor 4, transcript variant 1 | Fibroblast growth factor receptor 4 precursor | FGFR4 variant 2 | tyrosylprotein kinase | FGFR4 variant 3 | Ptd-FGFR4 | Tyrosine kinase related to fibroblast growth factor receptor | hydroxyaryl-protein kinase | JTK2 | Hydroxyaryl-protein kinase | CD334 | Fibroblast growth factor receptor 4 (isoform 1) | Tyrosylprotein kinase | Fibroblast growth factor receptor 4 (FGFR4) | protein-tyrosine kinase | Fibroblast growth factor receptor 4 (isoform 2) | Protein-tyrosine kinase | FGFR4_HUMAN | FGFR4 variant 5

FGFRI: A Protein Implicated in Tissue Growth, Development and Repair

FGFRI (Fibroblast growth factor receptor 4) is a protein that is expressed in various tissues throughout the body, including the skin, hair, nails, and bones. It plays a crucial role in cell growth, development, and maintenance. FGFRI is also involved in the regulation of cell-cell interactions and has been implicated in the development and progression of various diseases, including cancer.

The FGFRI gene has four splice variants, FGFRI-1, FGFRI-2, FGFRI-3, and FGFRI-4. FGFRI-1 is the most abundant and widely expressed splice variant, while FGFRI-4 is the least expressed. All four splice variants produce functional proteins, but the levels of these proteins vary depending on the tissue and developmental stage of the organism.

FGFRI is a transmembrane protein that consists of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain is involved in the formation of the protein's transmembrane region, while the transmembrane region is responsible for the protein's interactions with various signaling molecules. The intracellular domain is involved in the regulation of the protein's stability and function.

FGFRI is involved in the regulation of cell proliferation, differentiation, and survival. It has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of FGFRI are associated with the development of skin cancer, while low levels of FGFRI are associated with the development of bone and soft tissue cancer.

FGFRI is also involved in the regulation of cell-cell interactions and has been implicated in the development and progression of various diseases, including neurodegenerative disorders. For example, studies have shown that FGFRI is involved in the regulation of brain cell proliferation and that low levels of FGFRI are associated with the development of neurodegenerative disorders.

FGFRI has also been shown to play a role in the regulation of cellular signaling pathways. For example, studies have shown that FGFRI is involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and proliferation.

In addition to its role in cellular signaling pathways, FGFRI has also been shown to play a role in the regulation of cellular processes that are important for tissue growth and development. For example, studies have shown that FGFRI is involved in the regulation of cell-cell adhesion and that this regulation is important for the development and maintenance of tissues.

FGFRI is also involved in the regulation of cellular processes that are important for wound healing and tissue repair. Studies have shown that FGFRI is involved in the regulation of the production of matrix proteins, which are important for tissue repair and regeneration.

In conclusion, FGFRI is a protein that is involved in a wide range of cellular processes that are important for tissue growth, development, and repair. Its role in these processes makes it an attractive drug target and a potential biomarker for the diagnosis and treatment of various diseases. Further research is needed to fully understand the functions of FGFRI and to develop effective therapies that target this protein.

Protein Name: Fibroblast Growth Factor Receptor 4

Functions: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling

The "FGFR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGFR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4 | FIGLA | FIGN | FIGNL1 | FIGNL2 | FILIP1 | FILIP1L | FILNC1 | FIP1L1 | FIRRE | FIS1 | FITM1 | FITM2 | Five friends of methylated CHTOP complex | FIZ1 | FJX1 | FKBP10 | FKBP11 | FKBP14 | FKBP15 | FKBP1A | FKBP1A-SDCBP2 | FKBP1B | FKBP1C | FKBP2 | FKBP3 | FKBP4 | FKBP5 | FKBP6 | FKBP7 | FKBP8 | FKBP9 | FKBP9P1 | FKBPL | FKRP | FKSG29 | FKTN | FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA